{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:27:39Z","timestamp":1789540059954,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["1718-HQ-000027"],"award-info":[{"award-number":["1718-HQ-000027"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015150","name":"St. Michael's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clinbiochem.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T02:05:29Z","timestamp":1668218729000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply"],"prefix":"10.1016","volume":"111","author":[{"given":"Sarah R.","family":"Delaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Konforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Palaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Beriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2022.11.003_b0005","unstructured":"CDC National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. (Accessed December 2021)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0010","unstructured":"Illicit Drug Toxicity Deaths in British Columbia. https:\/\/www2.gov.bc.ca\/gov\/content\/life-events\/death\/coroners-service\/statistical-reports (Accessed December 2021)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0015","unstructured":"Toronto Overdose Information System. https:\/\/www.toronto.ca\/community-people\/health-wellness-care\/health-inspections-monitoring\/toronto-overdose-information-system\/ (Accessed April 2022)."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.003_b0020","doi-asserted-by":"crossref","first-page":"e2112865","DOI":"10.1001\/jamanetworkopen.2021.12865","article-title":"Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, during the COVID-19 Pandemic","volume":"4","author":"Gomes","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths \u2014 United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12954-021-00546-9","article-title":"Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications","volume":"18","author":"Bowles","year":"2021","journal-title":"Harm Reduction Journal"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.003_b0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/dar.13237","article-title":"Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings","volume":"40","author":"Ti","year":"2021","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0040","author":"Gomes","year":"2021"},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0045","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid and Stimulant-Related Harms in Canada. Ottawa: Public Health Agency of Canada; December 2021. Https:\/\/Health-Infobase.Canada.ca\/Substance-Related-Harms\/Opioids-Stimulants\/. (Accessed December 2021)."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.003_b0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1373\/jalm.2017.023341","article-title":"Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients","volume":"2","author":"Jannetto","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drugpo.2018.10.001","article-title":"Drug checking as a potential strategic overdose response in the fentanyl era","volume":"62","author":"Laing","year":"2018","journal-title":"Int. J. Drug Policy."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.003_b0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/add.15734","article-title":"Drug checking services for people who use drugs: a systematic review","volume":"117","author":"Maghsoudi","year":"2022","journal-title":"Addiction."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.003_b0065","article-title":"Evaluating networked drug checking services in Toronto, Ontario: Study protocol and rationale","volume":"17","author":"Maghsoudi","year":"2020","journal-title":"Harm Reduction J."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0070","first-page":"19","article-title":"A high-throughput broad-spectrum LC\/MS assay for psychoactive substances in urine","author":"Konforte","year":"2016","journal-title":"Can Soc Clin Chem. Published online"},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clinbiochem.2018.01.013","article-title":"Rapid identification of cyclopropyl fentanyl\/crotonyl fentanyl in clinical urine specimens: A case study of clinical laboratory collaboration in Canada","volume":"53","author":"Palaty","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106752","article-title":"High prevalence of co-occurring substance use in individuals with opioid use disorder","volume":"114","author":"Mahoney","year":"2021","journal-title":"Addict. Behav."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.003_b0085","doi-asserted-by":"crossref","first-page":"e192851","DOI":"10.1001\/jamanetworkopen.2019.2851","article-title":"Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine","volume":"2","author":"LaRue","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.003_b0090","doi-asserted-by":"crossref","first-page":"e1918514","DOI":"10.1001\/jamanetworkopen.2019.18514","article-title":"Evaluation of Trends of Near-Real-Time Urine Drug Test Results for Methamphetamine, Cocaine, Heroin, and Fentanyl","volume":"3","author":"Twillman","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0095","unstructured":"Drug Enforcement Administration U, Control Division D. National Forensic Laboratory Information System: NFLIS-Drug 2019 Annual Report. https:\/\/www.nflis.deadiversion.usdoj.gov\/ (Accessed February 2022)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0100","first-page":"bkab106","article-title":"Etizolam Blood Concentrations in 191 Forensic Cases in Ontario Canada (2019\u20132020). [Epub ahead of print]","volume":"28","author":"Watts","year":"2021","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.003_b0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jat\/bkaa070","article-title":"Flualprazolam Blood Concentrations in 197 Forensic Investigation Cases","volume":"45","author":"Papsun","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0110","unstructured":"March 2020 Note to Harm Reduction Programs in Ontario. www.cdpe.org\/project\/drug-checking-services (Accessed April 2022)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0115","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2015.14242","article-title":"Focused use of drug screening in overdose patients increases impact on management","volume":"145","author":"Erdmann","year":"2015","journal-title":"Swiss Medical Weekly."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.003_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/emj.2003.012344","article-title":"A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department","volume":"21","author":"Fabbri","year":"2004","journal-title":"Emerg. Med. J."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.003_b0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/emj.20.1.25","article-title":"Comprehensive drug screening in decision making of patients attending the emergency department for suspected drug overdose","volume":"20","author":"Fabbri","year":"2003","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0130","doi-asserted-by":"crossref","unstructured":"Montanari E, Madeo G, Pichini S, Busard\u00f2 FP, Carlier J. Acute Intoxications and Fatalities Associated with Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review. [Epub ahead of print] Ther Drug Monit. 2022 Feb 9. doi: 10.1097\/FTD.0000000000000970.","DOI":"10.1097\/FTD.0000000000000970"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.003_b0135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0140","unstructured":"National Drug Early Warning System. https:\/\/ndews.org\/. (Accessed October 2022)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0145","unstructured":"National Forensic Laboratory Information System. https:\/\/www.nflis.deadiversion.usdoj.gov\/. (Accessed October 2022)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0150","unstructured":"Data from the UNDOC early warning advisory on new psychoactive substances: Global emergence of NPS. https:\/\/www.unodc.org\/unodc\/en\/scientists\/ewa\/data.html. (Accessed October 2022)."},{"key":"10.1016\/j.clinbiochem.2022.11.003_b0155","unstructured":"AACC Position Statement Stopping the Opioid Epidemic: Integral Role of Clinical Laboratorians. Published online 2019. https:\/\/www.aacc.org\/advocacy-and-outreach\/position-statements\/2019\/stopping-the-opioid-epidemic-integral-role-of-clinical-laboratorians. (Accessed April 2022)."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022002405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022002405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:59:11Z","timestamp":1757865551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912022002405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"alternative-id":["S0009912022002405"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.11.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}